Oversubscribed Seed round led by Meridian Street Capital and B Capital
NEW YORK–(BUSINESS WIRE)–Isaac Health, a digital health company emerging as a national leader for brain health, announced today the successful completion of its oversubscribed $5.7 million Seed round. The round was led by Meridian Street Capital and B Capital with participation from Primetime Partners, Co-Found Partners, VU Venture Partners, and AirAngels.
More than 20 states in the U.S. are classified as a “dementia neurology desert”1 by the Society of Actuaries2, while 61% of cases of dementia3 and 92% cases of mild cognitive impairment4 go undiagnosed. The need for specialist care is further exacerbated by the FDA’s recent approval of a disease modifying therapy for early-stage Alzheimer’s disease which requires specialist evaluation and follow-up.
In response, Isaac Health is redefining the future of brain healthcare by harnessing cutting-edge technology and predictive machine learning to identify patients with different cognitive and brain health conditions and enable center-of-excellence-level care to be scaled across communities.
“We are thrilled to have secured this significant investment, which reflects the confidence our investors have in the potential for Isaac Health to be the category defining player for brain health,” said Julius Bruch, CEO of Isaac Health. “This funding will enable us to accelerate our mission of providing high-quality patient-centered care for the evaluation and management of dementia and many other brain health conditions.”
Isaac Health partners with health systems and health plans to screen, diagnose, treat, and manage their populations who have brain health conditions, starting with dementia. This strategic funding empowers Isaac Health to further develop and expand its innovative brain health provider platform, driving advancements in the screening, diagnosis, treatment, and management of brain health and dementia. The funding is instrumental in scaling operations and driving strategic partnerships to position Isaac Health as a leader in the rapidly evolving brain health landscape.
“We are currently at a historic inflection point for brain health with the first full FDA-approved disease modifying treatment for early-stage Alzheimer’s disease, and the company’s commitment to innovation, coupled with the vast potential size of the brain health market, strongly aligns with our vision for the future of healthcare,” said Karen Page, General Partner at B Capital. “We look forward to collaborating with Isaac Health as they continue to make significant strides in transforming patient care.”
“Brain health should mean more than just supporting the late stages of disease. It should mean early detection and proactive care, in and beyond the four walls of a clinic,” said George Ribaroff, Partner at Meridian Street Capital. “Isaac Health, through their novel model and technology, has the potential to scale the gold-standard of care. We are excited to partner with Isaac Health as they play a real role in reducing the burden of dementia and other brain conditions on individuals and their families.”
About Isaac Health
Launched in 2022, Isaac Health offers a virtual brain health and memory clinic platform with the goal of dramatically improving access to constrained brain health services. Isaac Health partners with health systems and payers to screen, diagnose, treat, and manage populations with brain health conditions such as dementia. Isaac Health is also available to patients or their caregivers directly as a memory clinic service at myisaachealth.com.
1 Defined by a ratio of 9 or less of general adult neurologists to 10,000 ADRD (Alzheimer’s Disease and Related Dementias) population projected for 2025
2 “Dementia Neurology Deserts and Long-Term Care Insurance Claims Experience in the United States – How Does Limited Supply of Neurologists Correlate with Claims Experience Data?”. Report by Anitha Rao and Robert Eaton, published by the Society of Actuaries May 2021
3 Lang L, Clifford A, Wei L, et al. Prevalence and determinants of undetected dementia in the community: a systematic literature review and a meta-analysis. BMJ Open 2017;7:e011146. Doi: 10.1136/bmjopen-2016-011146
4 Liu, Y., Jun, H., Becker, A. et al. Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population. J Prev Alzheimers Dis (2023). https://doi.org/10.14283/jpad.2023.131
Julius Bruch (email@example.com)